A study compared three biomarkers in people with Alzheimer’s disease
Original source
Comparison of TDP-43, NfL, and GFAP in cerebrospinal fluid and serum in Alzheimer's disease. (opens in a new tab)Compass holds only the headline and link for this source, so the summary below is necessarily brief. Please read the original.
Related topics
A journal article reports a comparison of TDP-43, neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid and blood serum in Alzheimer’s disease. The available source does not report findings in amyotrophic lateral sclerosis (ALS) or motor neurone disease (MND).
Why this matters
This does not establish a new ALS/MND diagnostic test, treatment, or disease finding. Its relevance to people with ALS/MND cannot be determined from the available information.
Limitations and context
Only the article title and publication metadata are available. The study population, methods, results, sample size and conclusions are unknown, and the article concerns Alzheimer’s disease rather than ALS/MND.